Table 3.

Multivariate analyses for adverse events during the first cycle of treatment with S‐1 plus oxaliplatin and S‐1 plus cisplatin

	Leukopenia	Neutropenia	Thrombocytopenia	Nausea	Vomiting	Diarrhea	Stomatitis
S‐1 plus oxaliplatin
Sex, female vs male
OR, 95%CI	1.9, 1.1‐3.3	2.2, 1.3‐3.7	0.70, 0.39‐1.32	2.0, 1.2‐3.3	2.8, 1.6‐4.9	1.3, 0.78‐2.3	0.73, 0.28‐1.9
P value	.015	.0036	.25	.0096	.0004	.30	.51
CCr, 70 mL/min ≤ vs 70 mL/min >
OR, 95%CI	0.78, 0.43‐1.4	0.55, 0.31‐0.97	0.82, 0.43‐1.5	0.94, 0.55‐1.6	0.68, 0.35‐1.3	0.56, 0.32‐1.0	0.52, 0.20‐1.3
P value	.41	.039	.53	.83	.25	.053	.17
BMI, median ≤ vs median > per gender
OR, 95%CI	0.72, 0.43‐1.2	0.81, 0.50‐1.3	1.2, 0.67‐2.0	0.76, 0.48‐1.2	0.85, 0.48‐1.5	1.3, 0.78‐2.1	1.2, 0.55‐2.8
P value	.20	.40	.61	.26	.59	.33	.60
Age, 70 ≤ vs 70 >
OR, 95%CI	0.91, 0.50‐1.6	0.63, 0.36‐1.1	0.64, 0.34‐1.2	1.1, 0.63‐1.9	0.77, 0.40‐1.5	0.95, 0.53‐1.7	1.0, 0.41‐2.6
P value	.75	.12	.18	.79	.45	.86	.93
PS, 1 or 2 vs 0
OR, 95%CI	0.90, 0.53‐1.5	0.60, 0.36‐1.0	0.92, 0.53‐1.6	0.92, 0.57‐1.5	1.8, 1.0‐3.1	1.1, 0.63‐1.8	2.0, 0.90‐4.3
P value	.69	.057	.78	.75	.040	.84	.088
Peritoneal dissemination, yes vs no
OR, 95%CI	0.97, 0.53‐1.8	1.1, 0.62‐1.9	1.1, 0.58‐2.1	1.3, 0.74‐2.3	0.80, 0.40‐1.6	1.3, 0.75‐2.4	1.4, 0.56‐3.5
P value	.92	.75	.78	.36	.52	.32	.47
S‐1 plus cisplatin
Sex, female vs male
OR, 95%CI	0.98, 0.60‐1.6	0.66, 0.40‐1.1	0.52, 0.31‐0.88	1.4, 0.86‐2.3	2.8, 1.7‐4.9	1.5, 0.87‐2.4	1.9, 1.1‐3.4
P value	.94	.11	.014	.17	.0001	.15	.022
CCr, 70 mL/min ≤ vs 70 mL/min >
OR, 95%CI	0.59, 0.36‐0.99	0.60, 0.35‐1.0	0.78, 0.47‐1.3	0.74, 0.44‐1.2	0.55, 0.31‐0.98	0.91, 0.54‐1.6	0.94, 0.52‐1.7
P value	.044	.06	.35	.25	.042	.74	.84
BMI, median ≤ vs median > per gender
OR, 95%CI	0.67, 0.42‐1.1	0.53, 0.33‐0.85	0.83, 0.52‐1.3	1.2, 0.76‐1.9	0.85, 0.49‐1.5	0.68, 0.42‐1.1	0.77, 0.44‐1.3
P value	.086	.0084	.43	.44	.55	.12	.34
Age, 70 ≤ vs 70 >
OR, 95%CI	1.3, 0.77‐2.2	0.98, 0.57‐1.7	1.9, 1.1‐3.2	0.84, 0.51‐1.4	1.1, 0.59‐1.9	1.2, 0.72‐2.1	1.8, 1.0‐3.2
P value	.33	.94	.016	.51	.85	.46	.045
PS, 1 or 2 vs 0
OR, 95%CI	1.0, 0.60‐1.6	1.5, 0.87‐2.4	0.89, 0.54‐1.5	1.1, 0.67‐1.8	1.1, 0.60‐1.9	1.4, 0.84‐2.3	1.3, 0.74‐2.3
P value	.91	.15	.64	.71	.86	.20	.36
Peritoneal dissemination, yes vs no
OR, 95%CI	1.6, 0.91‐2.8	0.93, 0.53‐1.7	1.0, 0.59‐1.8	1.5, 0.85‐2.6	1.2, 0.65‐2.3	0.76, 0.42‐1.4	0.82, 0.41‐1.6
P value	.11	.81	.91	.16	.54	.38	.56

The median BMI of female patients treated with S‐1 plus oxaliplatin or S‐1 plus cisplatin were 20.4 kg/m², and the BMI of males were 21.6 kg/m².

Abbreviations: BMI, body mass index; CCr, creatinine clearance; CI, confidence interval; OR, odds ratio; PS performance status.